GLUE · Insider trading · 13F holders · Congress trades
Monte Rosa Therapeutics, Inc. (GLUE)
Who is buying and selling GLUE: company insiders on SEC Form 4, hedge funds and superinvestors on Form 13F, and members of Congress under the STOCK Act. Every figure links to the filing or page it comes from.
- 13F filers holding
- 25
- Insider buys, 90 days
- $0
- Insider sales, 90 days
- $137.28
- Congress trades, 12 months
- 0
GLUE at a glance
- Between Aug 1, 2026 and Oct 29, 2026, 1 GLUE insider filed 1 sale worth $137.28 on SEC Form 4, and no open-market purchases.
- 25 13F filers hold GLUE among their 50 largest positions, worth $1.1B combined, including Julian and Felix Baker. The biggest bets by portfolio weight are NEA Management Company, LLC (11.7%), Aisling Capital Management LP (8.0%) and Boone Capital Management LLC (3.5%). In their latest 13Fs, 2 managers opened a new position and 3 added to one.
- No member of Congress has disclosed a trade in GLUE.
- GLUE last closed at $10.87 on Oct 29, 2026.
GLUE insider trading
Between Aug 1, 2026 and Oct 29, 2026, 1 GLUE insider filed 1 sale worth $137.28 on SEC Form 4, and no open-market purchases.
| Filed | Insider | Role | Trade | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|---|
| Oct 6, 2026 | Bowen Matthew | Principal Accounting Officer | Sale | 13 | $10.56 | $137.28 | SEC |
Who owns GLUE? Hedge funds and superinvestors
25 13F filers hold GLUE among their 50 largest positions, worth $1.1B combined, including Julian and Felix Baker. The biggest bets by portfolio weight are NEA Management Company, LLC (11.7%), Aisling Capital Management LP (8.0%) and Boone Capital Management LLC (3.5%). In their latest 13Fs, 2 managers opened a new position and 3 added to one.
Superinvestors holding GLUE: Julian and Felix Baker 0.5%
| Manager | % of portfolio | Value | Shares | Last quarter | 13F |
|---|---|---|---|---|---|
| NEA Management Company, LLCHedge fund | 11.7% | $186.2M | 7,692,298 | +0.0% shares | Q2 2026 |
| TCG Crossover Management, LLCHedge fund | 2.7% | $111.9M | 4,622,151 | +0.0% shares | Q2 2026 |
| Vestal Point Capital, LPHedge fund | 2.6% | $111.3M | 4,600,000 | +27.7% shares | Q2 2026 |
| Bvf Inc/ilInvestment manager | 2.8% | $108.0M | 4,460,886 | +0.0% shares | Q2 2026 |
| Julian and Felix BakerHedge fund | 0.5% | $105.2M | 4,345,736 | +0.0% shares | Q2 2026 |
| Montanova Capital, LLCHedge fund | 1.8% | $85.9M | 3,549,539 | -16.0% shares | Q2 2026 |
| Versant Venture Management, LLCVenture capital | 47.3% | $77.0M | 3,180,780 | +0.0% shares | Q2 2026 |
| Braidwell LPHedge fund | 2.3% | $59.3M | 2,451,562 | -23.5% shares | Q2 2026 |
| Aisling Capital Management LPHedge fund | 8.0% | $37.6M | 1,555,664 | +0.0% shares | Q2 2026 |
| Bellevue Group AGInvestment manager | 0.6% | $28.8M | 1,190,000 | -4.8% shares | Q2 2026 |
| Mpm Bioimpact LLCHedge fund | 1.7% | $28.1M | 1,161,081 | -1.3% shares | Q2 2026 |
| Silverarc Capital Management, LLCHedge fund | 3.0% | $26.8M | 1,108,295 | -44.6% shares | Q2 2026 |
| Frazier Life Sciences Management, L.P.Hedge fund | 0.5% | $24.2M | 1,000,000 | +0.0% shares | Q2 2026 |
| Nextech Invest Ltd.Hedge fund | 0.9% | $18.4M | 761,153 | +150.2% shares | Q2 2026 |
| Opaleye Management Inc.Hedge fund | 1.6% | $18.0M | 745,000 | — | Q2 2026 |
| Nantahala Capital Management, LLCHedge fund | 1.0% | $15.8M | 651,993 | — | Q2 2026 |
| Boone Capital Management LLCHedge fund | 3.5% | $14.9M | 615,287 | New | Q2 2026 |
| Parkwood LLCInvestment manager | 0.9% | $12.2M | 505,000 | — | Q2 2026 |
| Alphabet Inc.Corporation | 0.0% | $9.0M | 372,474 | -45.6% shares | Q2 2026 |
| Casdin Capital, LLCHedge fund | 0.2% | $4.5M | 186,014 | +0.0% shares | Q2 2026 |
| Stempoint Capital LPHedge fund | 0.6% | $3.7M | 153,544 | — | Q2 2026 |
| Exome Asset Management LLCHedge fund | 2.0% | $3.3M | 137,115 | -23.6% shares | Q2 2026 |
| Diadema Partners LPHedge fund | 0.7% | $1.9M | 78,391 | -58.1% shares | Q2 2026 |
| Tetragon Partners GP LtdHedge fund | 0.2% | $1.4M | 56,052 | New | Q2 2026 |
| Act Capital Management, LLCHedge fund | 0.6% | $847K | 35,000 | +55.6% shares | Q2 2026 |
Each manager counts with its latest 13F (Q2 2026: 25). Screen GLUE in the grand portfolio →
GLUE stock trades by members of Congress
No member of Congress has disclosed a trade in GLUE.
GLUE questions and answers
Are insiders buying GLUE stock?
Between Aug 1, 2026 and Oct 29, 2026, 1 GLUE insider filed 1 sale worth $137.28 on SEC Form 4, and no open-market purchases.
Which hedge funds own GLUE?
25 13F filers hold GLUE among their 50 largest positions, worth $1.1B combined, including Julian and Felix Baker. The biggest bets by portfolio weight are NEA Management Company, LLC (11.7%), Aisling Capital Management LP (8.0%) and Boone Capital Management LLC (3.5%). In their latest 13Fs, 2 managers opened a new position and 3 added to one.
Has Congress traded GLUE?
No member of Congress has disclosed a trade in GLUE.
Who is the largest holder of GLUE?
Among 13F filers, NEA Management Company, LLC reports the largest GLUE position, $186.2M (7,692,298 shares) in its Q2 2026 13F. The biggest bet by portfolio weight is NEA Management Company, LLC's: 11.7% of its portfolio.
Cite or share this
Free to use with a link back. The data updates every filing day.